Document:

EX-10.8
                              License Agreement dated November 12, 1999
<PAGE>
                                   EXHIBIT 10.8

                                LICENSE AGREEMENT
                              (Random Metering System)

         THIS LICENSE AGREEMENT ("Agreement") is made this 12'h day of November,
1999,  by  and  between  NVID  International,   Ins.,  a  Delaware   corporation
("Co-Licensor" or "Licensors") and EHPC IONIZATION,  Ltd, an English corporation
("Co-Licensor"  or "Licensors") 'and Innovative  Medical Services,  a California
corporation ("Licensee").

WHEREAS,  Licensors  holds,  marketing and  distribution  rights to the products
known as RMS ("RMS" or the  "Licensed  Product').  RMS is patent  pending in the
USA, Canada,  Australia,  Japan, New Zealand, EP and several other countries (to
be  disclosed  by the  closing  date),  for the killing of  bacterial  and other
biological  contaminants from a water system as more  particularly  described in
the attached Exhibit A: PATENT and EHPC IONIZATION Ltd., License Agreement; and

WHEREAS,  Licensors desires to license certain marketing and distribution rights
to the Licensed  Product to the Licensee on the terms and  conditions  set forth
herein.

THEREFORE, Licensors and Licensee agree as follows:

1.        Representations And Warranties Of Licensee

As an  inducement  to,  and  to  obtain  the  reliance  of  Licensors,  Licensee
represents and warrants as follows:

         1.1.  Organization,  Good  Standing,  Power,  Etc.  Licensee  (i)  is a
corporation duly organized,  validly existing and in good standing under the law
of the State of California;  (ii) is qualified or authorized to do business as a
foreign  corporation  and is in good  standing  in all  jurisdictions  in  which
qualification  or  authorization  may be required;  and (iii) has all  requisite
corporate power and authority,  licenses and permits to own or lease and operate
its  properties  and carry on its business as presently  being  conducted and to
execute,  deliver and perform this  Agreement and  consummate  the  transactions
contemplated hereby.

         1.2. Capitalization.  The authorized capital stock of Licensee consists
solely of 20,000,000 shares of Common Stock, no par value, (the "Licensee Common
Stock"),  of which,  on the date hereof shares are issued and outstanding and no
shares are held in the  treasury  of  Licensee.  In  addition  the  Company  has
5,000,000  shares of Preferred  Stock  authorized,  none of which are  presently
outstanding.  All of such issued and  outstanding  shares of the Licensee Common
Stock  have been duly  authorized  and  validly  issued  and are fully  paid and
non-assessable with no personal liability attaching to the ownership thereof and
were not issued in violation of the preemptive or other rights of any person.

         1.3.     Authorization of Agreement.  This Agreement has been or will
be at closing duly and validly  authorized,  executed and delivered by Licensee.

         1.4.  Compliance with Applicable Laws. The conduct by Licensee of their
business does not violate or infringe on any domestic (federal,  state or local)
or foreign law,  statute,  ordinance  or  regulation  now in effect,  or, to the
knowledge of Licensee  proposed to be adopted,  the  enforcement  of which would
materially  and adversely  affect its business or the value of its properties or
assets.

         1.5. Exchange Act Filings and Financial Statements.  Licensee has filed
all  reports  required  of it with the United  States  Securities  and  Exchange
Commission (the SEC) pursuant to Section 12(g) of the Securities Exchange Act of
1934 (the 1934  Act)  including  without  limitation,  registration  statements,
10-KSB's,  10 QSB's,  Form 8's, etc. for each of the annual,  quarterly or other
fiscal  periods from the first to latest such filings  since  Licensee  first so
registered as a public company.

         1.6.     Recognition of Licensors Trade Secrets.
<PAGE>

                  1.6.1. Licensee acknowledges and agrees that the documentation
         and data provided pursuant to the Test Marketing Period described below
         are "Licensors Trade Secrets" and constitute  valuable  property rights
         of Licensors.

                  1.6.2. Licensee agrees that during the term of this Agreement,
         or following its termination and for all times thereafter, it will keep
         secret and  confidential  all Licensors Trade Secrets which it knows or
         may hereafter come to know as a result of the relationship  established
         by this  Agreement.  The Licensors Trade Secrets shall not be disclosed
         by Licensee to third parties and shall be kept secret and  confidential
         except (i) to the  extent  that the same have  entered  into the public
         domain by means other than improper  actions by Licensee or (ii) to the
         extent that the  disclosure  thereof  may be  required  pursuant to the
         order of any court or other governmental body.

                  1.6.3. It is understood and recognized by Licensee that in the
         event of any violation by Licensee of the  provisions  of  subparagraph
         1.6 above,  Licensors'  remedy at law will be inadequate  and Licensors
         will  suffer  irreparable  injury.  Accordingly,  Licensee  consents to
         injunctive and other appropriate  equitable relief upon the institution
         of legal  proceedings  therefore  by  Licensors in order to protect the
         Licensors Trade Secrets.  Such relief shall be in addition to any other
         relief to which Licensors may be entitled at law or in equity.

                  1.6.4.  Licensee  shall cause their  employees  who shall have
         access to Licensors Trade Secrets  hereof,  to sign  appropriate  Trade
         Secrecy Agreements in the form of Exhibit "A" annexed hereto and made a
         part hereof.

2.       Representations And Warranties Of Licensors

As an  inducement  to,  and  to  obtain  the  reliance  of  LICENSEE,  LICENSORS
represents and warrants as follows:

         2.1.  Organization,  Good  standing,  Power,  Etc.  Licensors  (i) is a
corporation duly organized, validly existing and in good standing under the laws
of their respective federal,  state, local or foreign governmental or regulatory
bodies  and (ii) has all  requisite  corporate  power and  authority,  licenses,
permits and  franchises to own or lease and operate its  properties and carry on
its business as presently  being  conducted and to execute,  deliver and perform
this Agreement and consummate the transactions contemplated hereby.

         2.2.     Authorization of Agreement.  This Agreement has been or will
be at closing duly and validly authorized,  executed and delivered by Licensors.

         2.3. Material Contracts There has not occurred any default by Licensors
or any event which with the lapse of time or the  election  of any person  other
than Licensors will become a default,  except  defaults,  if any, which will not
result in any material loss to or liability of Licensors.

         2.4.     Permits,  Licenses,  Etc. Licensors has all permits, licenses,
orders and approvals of federal,  state, local or foreign  governmental  or
regulatory  bodies  that are  required  in order to permit  it to carry on their
business  as  presently conducted.

         2.5.  Compliance with Applicable  Laws. The conduct by Licensors of its
business  does not  violate or infringe  upon any  domestic  (federal,  state or
local) or foreign law,  statute,  ordinance or regulation now in effect,  or, to
the  knowledge of Licensors  proposed to be adopted,  the  enforcement  of which
would  materially  and  adversely  affect  its  business  or  the  value  of its
properties or assets.

         2.6. Litigation.  There is no material claim, action, suit, proceeding,
arbitration,  investigation  or  inquiry  pending  before  any  federal,  state,
municipal,  foreign or other court or  governmental  or  administrative  body or
agency, or any private  arbitration  tribunal,  or to the knowledge of Licensors
threatened, against, relating to or affecting Licensors or any of its properties
or business,  or the  transactions  contemplated by this  Agreement;  nor to the
knowledge of Licensors is there any basis for any such material  claim,  action,
suit,  proceeding,  arbitration,  investigation  or  inquiry  which may have any
adverse  effect upon the assets,  properties  or business of  Licensors,  or the
transactions contemplated by this Agreement.  Neither Licensors nor any officer,
director,  partner or employee of Licensors, has been permanently or temporarily
enjoined  by order,  judgment  or decree of any court or other  tribunal  or any
agency from engaging in or continuing any conduct or practice in connection with

<PAGE>

the business  engaged in by Licensors.  There is not in existence at present any
order, judgment or decree of any court or other tribunal or any agency enjoining
or requiring  Licensors to take any material  action of any kind or to Licensors
and its business, properties or assets are subject or bound. Licensors is not in
default under any order, license,  regulation or demand of any federal, state or
municipal  or other  governmental  agency or with  respect to any  order,  writ,
injunction or decree of any court which would have a materially  adverse  impact
upon Licensors' operations or affairs.

         2.7. Other  Information.  None of the  information  and documents which
have  been   furnished  or  made   available  by   LICENSORS,   or  any  of  its
representatives  to LICENSEE or any of their  representatives in connection with
the  transactions   contemplated  by  this  Agreement  is  materially  false  or
misleading or contains any material  misstatements of fact or omits any material
fact  necessary  to be  stated  in  order  to make the  statements  therein  not
misleading.

         2,8.  Covenant  to Refrain  from  Trading in Licensee  Securities.  The
Licensors, its executive officers and directors represent and warrant that since
August 1, 1999 they have not engaged in trading of Licensee securities and until
such time that  Licensee  has  announced  the  Closing  of this  Agreement,  the
Licensors,  its executive  officers and directors  will not engage in trading of
Licensee securities.

         2.9.  Authority  to grant a License  Pursuant  to the  Licensors',  the
holder of the patents for the  Licensed  Product and the  knowledge  and consent
thereof,  the  Licensors  has the right and  authority  to grant the license set
forth in this Agreement to the Licensees.

         2.10.  Compliance with  Environmental  Laws Licensors has not caused or
permitted  its  business,   properties,  or  assets  to  be  used  to  generate,
manufacture,  refine,  transport,  treat, store,  handle,  dispose of, transfer,
produce,  or process any Hazardous  Substance  (as such term is defined  herein)
except in compliance  with all  applicable  laws,  rules,  regulations,  orders,
judgments,  and  decrees,  and has not caused or  permitted  the  Release of any
Hazardous  Substance on or off the site of any property of  Licensors.  The term
'Hazardous  Substance' shall mean any hazardous waste, as defined by 42 U.S.C. '
6903(5),  any  hazardous  substance,  as  defined  by 42  U.S.C.'  601(14),  any
pollutant  or  contaminant,  as defined by 42  U.S.C.'  9601(33),  and all toxic
substances,  hazardous materials,  or other chemical substances regulated by any
other* law, rule, or regulation.  The term 'Release'  shall have the meaning set
forth in 42 U.S.C. ' 9601(22).

3.       Marketing, Manufacturing and Distribution Licenses

                  3.1.1.  Grant of License  far R MS.  Subject o Closing of this
         Agreement as set forth below,  Licensors grants to the Licensee a three
         year, exclusive license for Australia, North, Central and South America
         and a  non-exclusive  license for the Mexico and other World markets to
         market and distribute RMS for the Markets as set forth below.  Provided
         there has been no breach of this  Agreement by the  Licensee  which has
         not been cured  within  thirty days of written  notice of such  breach,
         this geographic license shall  automatically  renew on terms herein for
         subsequent additional three year terms.

                  3.1.2. Internet Market. IMS shall have the right to market via
         the Internet at it's sole discretion

                  3.1.2.1.  The Market The  Healthcare  Market shall be
                  all  water  purification  and  disinfections  systems  for the
                  killing of bacterial and other biological contaminants and the
                  removal  of  bio-film   for   commercial/private:   hospitals,
                  clinics,  surgical  centers,  doctors'  offices  or medical or
                  health related facilities,  including military and medical and
                  health facilities.
<PAGE>

                           3.1.2.2. Registration Certification or Licensing
                  Payments. Upon Closing of this Agreement and except as
                  set forth below, Licensors (NVID) agrees to bear the cost of
                  any registration, certification or licensing fees or
                  payments required to market and sell RMS to the Healthcare
                  Market. (UL or Edison Testing Lab certification)

                           3.1.2.3.   Licensing   Fee.   Licensee  will  pay  to
                  Licensors,  a Licensing Fee totaling $210,000,  payable at the
                  rate of One Thousand, Five Hundred dollars ($1,500.00) per RMS
                  System sold plus sixteen and one half  percent  (16.5%) of the
                  manufactured  cost of the RMS system sold by the Licensee.  At
                  such time that the  Licensee has paid  $210,000 of  Continuing
                  Licensee Fees,  the Continuing  Licensing Fee shall be sixteen
                  and one half percent (16.5%) of the  manufactured  cost of the
                  RMS system sold by the Licensee.

                           3.1.2.4. RMS Research Agreement payment. Upon Closing
                  of this Agreement,  Licensee shall reimburse  Fifteen Thousand
                  Four Hundred  dollars  ($15,400) to NVID (paid  8-26-99 to Dr.
                  Yu)  for  testing  the   effectiveness   of  the  RMS  against
                  Legionella.  Dr Yu and his staff  will  establish  a  Veterans
                  Administration Hospital Research Protocol for testing the RMS.

                           3.1.2.5.   Maintenance  of  License   Licensee  shall
                  maintain  its  license  for RMS by  meeting or  exceeding  the
                  following annual performance criteria:

                  3.1.2.5.1. $250,000 in gross sales within the I" year; and
                  3.1.2.5.2. $400,000 in gross sales within the 2"(degree)year;
                   and
                  3.1.2.5.3. $650,000 in gross sales within the 3`d year.

In the event,  Licensee  meets or exceeds the  performance  criteria  during the
initial  term  of  the  license,  the  license  shall  automatically  renew  for
subsequent three years terms.

4.        Closing.

         4.1. The Closing The Closing of this  Agreement  shall take place on or
before the thirtieth (30) calendar day following  execution of this Agreement or
such date as may be agreed  upon by the  parties,  (herein  called the  "Closing
Date"), at the offices of the Licensee.  At the Closing,  each of the respective
parties  hereto shall  execute,  acknowledge,  and deliver (or shall cause to be
executed,  acknowledged,  and delivered) any agreements,  resolutions,  or other
instruments  required by this  Agreement  to be so  delivered at or prior to the
Closing,  together with such other items as may be  reasonably  requested by the
parties  hereto and their  respective  legal  counsel in order to  effectuate or
evidence the transactions contemplated hereby.

5.       Special Covenants

         5.1. Me  Diligence.  The parties  hereto shall have up to and including
the  date  prior to  Closing  within  which  to  complete  their  due  diligence
investigations on the other party and the transaction contemplated hereunder. In
the event either party hereto decides,  in its sole  discretion,  not to proceed
with the Closing based on its due diligence  investigation,  it shall notify the
other in writing of such decision and this  Agreement  shall  terminate  without
obligation to the other party except as to the confidentiality provisions.

         5.2.  Exchange  of  Information.  Each party shall  cooperate  fully by
exchanging  information requested by the other party in a timely manner. Without
in any manner  reducing or otherwise  mitigating the  representations  contained
herein,  each party and/or its attorneys shall have the opportunity to meet with
the accountants and attorneys of the other party to discuss its respective legal
and  financial  condition  and  this  transaction.  If this  transaction  is not
completed,  all  documents  received by each party and/or its attorney  shall be
returned  to the  other  party and all such  information  so  received  shall be
treated as confidential in accordance with Paragraph 8.10.

         5.3.  Distributor  Agreement.   After  Closing,  the  order,  purchase,
shipment, payment and other terms relevant to the wholesale purchase and sale of
the Licensed  Products pursuant to this Agreement shall be governed by the terms
of the form of  Purchase  Order  attached  hereto as Exhibit "B" and the Uniform
Commercial Code.
<PAGE>

6.       Conditions Precedent To Obligations Of Parties

         6.1.     Licensors' Closing  Conditions.  The obligations of Licensors
hereunder are subject to fulfillment prior to or at the Closing of each of the
following conditions:

                  6.1.1.  Representations and Warranties.  The representations
         and warranties of Licensee made pursuant to Paragraph
         1 above, shall be true and accurate in all material respects as of the
         Closing Date.

                  6.1.2.  Performance.  Licensee shall have  performed and
         complied with all  agreements and conditions  required by
         this Agreement to be performed or complied with by it prior to or at
         the Closing.

                  6.1.3. No Adverse Change.  There shall not have been, since
         the date of the latest audited financial statements of
         Licensee, any materially adverse change in Licensee's financial
         condition, assets, liabilities or business.

                  6.1.4.  Opinion  of  Licensee'  Counsel.  Licensee  shall have
         delivered  to  Licensors  an  opinion  of  Licensee's  counsel,  Dennis
         Brovarone,  Attorney at Law, dated the Closing Date to the effect that:
         (i) Licensee is a corporation  duly organized,  validly existing and in
         good  standing  under  the  laws of the  State of  California,  has all
         requisite  power to carry on its business as now being conducted and to
         execute,  deliver  and  perform  this  Agreement  and  to  perform  its
         obligations;  (ii)  Licensee  is duly  qualified  to do  business  as a
         foreign  corporation and is good standing in each jurisdiction in which
         the  nature of the  business  conducted  by it or the  property  owned,
         operated or leased by it makes such qualification necessary; (iii) this
         Agreement has been duly authorized by all necessary corporate action on
         the part of Licensee,  has been duly  executed and delivered by IMS and
         constitutes  the  legal,  valid  and  binding  obligation  of  Licensee
         enforceable  in  accordance  with its terms  except  as  enforceability
         thereof may be limited by the  insolvency  or other laws  affecting the
         rights of creditors and the enforcement of remedies;  (iv) Licensee has
         prepared  and filed with the SEC all  periodic  reports  required of it
         under the 1934 Act; (v) neither the execution, delivery and performance
         by Licensee of this  Agreement,  nor  compliance  by Licensee  with the
         terms and provisions hereof,  will conflict with, or result in a breach
         of the terms, conditions or provisions of, or will constitute a default
         under,  the  Articles  of  Incorporation  or Bylaws of  Licensee or any
         agreement or  instrument  known to such counsel to which  Licensee is a
         party or by which IMS or any of its  properties  or assets  are  bound;
         (vi) there are no  actions,  suits or  proceedings  pending  or, to the
         knowledge of such counsel, threatened against Licensee before any court
         or administrative  agency,  which have, in the opinion of such counsel,
         if  adversely  decided,  will have any material  adverse  effect on the
         business or  financial  condition  of Licensee or which  questions  the
         validity of this Agreement. In rendering his opinion,  counsel shall be
         allowed to rely on written representations of officers and directors of
         the Licensee as to factual  matters  without  independent  verification
         thereof.

                  6.1.5.  Current  Status with Sec and Exchange  Commission.
         Licensee shall have prepared and fled with the SEC all periodic reports
         required under the 1934 Act pursuant to Section 12(g) thereof.

                  6.1.6.  Due Diligence.  Licensors  shall have completed and be
         satisfied with its due diligence  investigation  of Licensee pursuant
         to Paragraph 5.1.

         6.2.     Licensee's  Closing  Conditions.  The obligations of Licensee
         hereunder are subject to fulfillment prior to or at the Closing of
         each of the following conditions:

                  6.2.1.  Representation and Warranties.  The representations
         and warranties of Licensors made pursuant to Paragraph
         2 above, shall be true and accurate in all material respects as
         of the Closing Date.
<PAGE>

                  6.2.2. No Adverse  Changes,  There shall not have been,  since
         the date of the latest audited financial  statements of Licensors,  any
         materially  adverse  change  in  their  financial  condition,   assets,
         liabilities or business.

                  6.2.3.  Opinion of Licensors'  Counsel.  Licensors  shall have
         delivered to Licensee,  an opinion of their  respective legal counsels,
         respectively,  dated the Closing Date to the effect that: (i) Licensors
         is a corporation duly organized,  validly existing and in good standing
         under the laws of their respective  states,  has all requisite power to
         carry on its business as now being  conducted  and to execute,  deliver
         and  perform  this  Agreement  and to  perform  its  obligations;  (ii)
         Licensors are duly qualified to do business and are in good standing in
         each  jurisdiction in which the nature of the business  conducted by it
         or  the   property   owned,   operated  or  leased  by  it  makes  such
         qualification necessary;  (iii) this Agreement has been duly authorized
         by all necessary  corporate  action on the part of Licensors,  has been
         duly  executed and delivered by Licensors  and  constitutes  the legal,
         valid and binding  obligation of Licensors,  enforceable  in accordance
         with its terms except as  enforceability  thereof may be limited by the
         insolvency  or other laws  affecting  the rights of  creditors  and the
         enforcement  of  remedies;  (iv)  neither the  execution,  delivery and
         performance by Licensors of this Agreement, nor compliance by Licensors
         with the terms and provisions hereof,  will conflict with, or result in
         a breach of the terms,  conditions or provisions of, or will constitute
         a default under,  the Articles of  Incorporation or Bylaws of Licensors
         or any agreement or instrument known to such counsel to which Licensors
         is a party or by which Licensors or any of its properties or assets are
         bound;  (v) there are no actions,  suits or proceedings  pending or, to
         the knowledge of such counsel,  threatened against Licensors before any
         court or administrative  agency, which, in the opinion of such counsel,
         if  adversely  decided,  will have any material  adverse  effect on the
         business or financial  condition of  Licensors or which  questions  the
         validity of this Agreement.  In rendering their opinion,  counsel shall
         be allowed to rely on written representations of officers and directors
         of the Licensors as to factual matters without independent verification
         thereof.

                  6.2.4.  Due Diligence.  Licensee shall have  completed and be
         satisfied  with its due diligence  investigation  of Licensors pursuant
         to Paragraph 5.1.

7.       Patent and Copyright Indemnity.

         7.1.  Licensors  warrants  that the use of the Licensed  Product by the
Licensee  pursuant to the terms hereof shall not constitute an  infringement  of
any existing  patent,  copyright or other right.  Subject to the  limitation set
forth below, Licensors hereby agrees to defend or settle any suit, proceeding or
claim brought against the Licensee based on a claim that the use of the Licensed
Products or any part thereof by the Licensee  constitutes an infringement of any
existing patent,  copyright or other right.  Subject to the limitation set forth
below,  Licensors  shall pay all damages or costs  awarded  against or expenses,
including attorneys' fees, incurred by the Licensee in such suit,  proceeding or
claim.  The prior  written  consent of the Licensee  shall be obtained  prior to
Licensor engaging legal counsel with respect to a claim or settlement thereof.

         7.2. In the event the Licensed Products or any part thereof shall be in
Licensors'  opinion likely to or shall become the subject of a claim for patent,
copyright,  or other  infringement,  Licensors shall, at its option and expense,
procure for the Licensee the right to continue  using such  affected part of the
Licensed Products or modify such affected part to become non-infringing.  Should
Licensors  elect to  remove  or  modify  such  infringing  part of the  Licensed
Products,  Licensors  shall  forthwith  replace  such part  with a  functionally
equivalent  non-infringing  part or take other appropriate action to insure that
the  Licensed  Products  conforms  to  the   Specifications  to  the  Licensee's
satisfaction, without cost to the Licensee.

         7.3.  In the event that  Licensors  shall  refuse or shall be unable to
supply or shall be prevented  from  supplying the Licensed  Products or any part
thereof to the Licensee,  or in the event that the  Licensee's  continued use of
the Licensed  Products  shall be prohibited  or enjoined at any time,  Licensors
shall  promptly  replace  all  affected  parts  of the  Licensed  Products  with
functionally equivalent  non-infringing parts or shall take such other action to
insure  that  the  Licensed  Products  conforms  to  the  Specifications  to the
Licensee's satisfaction, without cost to the Licensee.
<PAGE>

7.4.  Licensors  warrants that the Licensee shall suffer no  interruption of its
normal  business  activities or cycles as a result of any claimed  infringement,
any  litigation  referred to in Paragraph 7 hereof or any  replacement  of items
contemplated in Paragraphs 7 hereof.'

8.       Miscellaneous

         8.1.  Expenses and Further  Assurances.  The parties  hereto shall each
bear  their  respective  costs and  expenses  incurred  in  connection  with the
transactions contemplated by this Agreement. Each party hereto will use its best
efforts provide any and all additional information,  execute and deliver any and
all documents or other written  material and perform any and all acts  necessary
to carry out the intent of this  Agreement and to comply with U.S. and Brazilian
law.

         8.2.     Survival of Representations, Warranties and Covenants. All of
the representations, warranties and covenants made as of the date of this
Agreement and as of Closing, shall survive the closing of this transaction.

         8.3.     Successors and Assigns.  All  representations,  warranties,
covenants and  agreements in this Agreement  shall be binding  upon and shall
inure to the benefit of the parties  hereto and their  respective  heirs,
representatives,  successors  and assigns whether so expressed or not.

         8.4.  Governing Law. This Agreement and the legal  relations  among the
Parties hereto shall be governed by and construed in accordance with the laws of
the State of California and that the State or Federal Courts of California shall
be the  jurisdiction in which any legal  proceedings  relative to this Agreement
shall be brought. The foregoing notwithstanding, the Parties agree that prior to
litigation,  they will arbitrate any disputes relative to this Agreement through
the services of the offices of the American  Arbitration  Association in and for
San Diego, California.

         8.5.  Attorney's  Fees In any action  brought to enforce  the terms and
conditions of this Agreement, the prevailing party shall be entitled in addition
to any other remedies, its reasonable attorneys fees incurred in the prosecution
or defense of the action.

         8.6.     Section and Other  Headings.  The section and other headings
herein  contained are for convenience  only and shall not be construed as part
of this Agreement.

         8.7.     Counterparts.  This Agreement may be executed in any number
of counterparts and each counterpart  shall constitute an original instrument,
but all such separate counterparts shall constitute but one and the same
instrument.

         8.8. Entire Agreement.  This Agreement constitutes the entire agreement
between the parties hereto and supersedes all prior  agreements,  understandings
and  arrangements,  oral or written,  between the parties hereto with respect to
the subject matter hereof. This Agreement may not be amended or modified, except
by a written agreement signed by all parties hereto.

         8.9. Sever. Any term or provision of this Agreement which is invalid or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffectual
to the extent of such invalidity or  unenforceability  without rendering invalid
or  unenforceable  the  remaining  terms and  provisions  of this  Agreement  or
affecting  the validity or  enforceability  of any of the terms or provisions of
this Agreement in any other jurisdiction.

         8.10. Confidentiality.  Each party hereto agrees with the other parties
that, unless and until this Agreement has been  consummated,  or for a period of
one (1) year from the date of this Agreement if the transaction  contemplated by
this Agreement is not consummated it and its representatives will hold in strict
confidence  all data and  information  obtained  with respect to the other party
from any  representative,  Officer,  Director or employee,  or from any books or
records or from personal inspection, of such other party, and shall not use such
data or  information or disclose the same to others,  except:  (i) to the extent
such data or information has theretofore been publicly disclosed, is a matter of
public knowledge or is required by law to be publicly disclosed; and (ii) to the
extent  that  such data or  information  must be used or  disclosed  in order to
consummate  the  transactions  contemplated  by this  Agreement.  The  foregoing
notwithstanding, Licensee shall be authorized to publicly announce the execution
and closing of this  Agreement,  details  thereof and a description of Licensors
and the business conducted thereby.
<PAGE>

IN WITNESS WHEREOF,  the corporate  parties hereto have caused this Agreement to
be executed by their respective  Officers,  hereunto duly authorized,  as of the
date first above written.

NVID INTERNATIONAL, INC.
By:  David J Larson, President
By:  Michael Redden, Secretary

EHPC IONIZATION, Ltd.,
By:  Bruce Milden, Managing Director
By:  Carolyn Wilden, Company Secretary

INNOVATIVE MEDICAL SERVICES
By:  Michael L. Krall, President
By:  Dennis Atchley, Secretary

<PAGE>EX-10.9
                              License Agreement dated November 24, 1999

<PAGE>
                                   EXHIBIT 10.9

                                 LICENSE AGREEMENT
                                    (AXENORL)

         THIS LICENSE AGREEMENT  ("Agreement") is made this 24`" day of November
1999, by and between NVID  International,  Inc., a corporation  ("Licensor") and
Innovative Medical Services, a California corporation ("Licensee").

WHEREAS, Licensor holds all rights to the product known AXENOHL or the "Licensed
Product"),  being  patented  pending  products for the killing of bacterial  and
other biological contaminants from a water system as more particularly described
in the attached Exhibit A: PATENT PENDING; and

WHEREAS,  Licensor desires to license certain marketing and distribution  rights
to the Licensed  Products to the Licensee on the terms and  conditions set forth
herein.

THEREFORE, Licensor and Licensee agree as follows:

1.       Representations And Warranties Of Licensee

         As an inducement  to, and to obtain the reliance of Licensor,  Licensee
represents and warrants as follows:

         1.1.  Organization,  Good  Standing,  Power,  Etc.  Licensee  (i)  is a
corporation duly organized,  validly existing and in good standing under the law
of the State of California;  (ii) is qualified or authorized to do business as a
foreign  corporation  and is in good  standing  in all  jurisdictions  in  which
qualification  or  authorization  may be required;  and (iii) has all  requisite
corporate power and authority,  licenses and permits to own or lease and operate
its  properties  and carry on its business as presently  being  conducted and to
execute,  deliver and perform this  Agreement and  consummate  the  transactions
contemplated hereby.

         1.2. Capitalization.  The authorized capital stock of Licensee consists
solely of 20,000,000 shares of Common Stock, no par value, (the "Licensee Common
Stock"),  of  which,  on  the  date  hereof  4,562,242  shares  are  issued  and
outstanding and no shares are held in the treasury of Licensee.  In addition the
Company has 5,000,000  shares of Preferred Stock  authorized,  none of which are
presently outstanding. All of such issued and outstanding shares of the Licensee
Common Stock have been duly authorized and validly issued and are fully paid and
non-assessable with no personal liability attaching to the ownership thereof and
were not issued in violation of the preemptive or other rights of any person.

         1.3.     Authorization of Agreement.  This Agreement has been or will
be at Closing duly and validly  authorized,  executed and delivered by Licensee.

         1.4.  Compliance with Applicable Laws, The conduct by Licensee of their
business does not violate or infringe on any domestic (federal,  state or local)
or foreign law,  statute,  ordinance  or  regulation  now in effect,  or, to the
knowledge of Licensee  proposed to be adopted,  the  enforcement  of which would
materially  and adversely  affect its business or the value of its properties or
assets.

         1.5. Exchange Art Filings and Financial Statements.  Licensee has filed
all  reports  required  of it with the United  States  Securities  and  Exchange
Commission (the SEC) pursuant to Section 12(g) of the Securities Exchange Act of
1934 (the 1934  Act)  including  without  limitation,  registration  statements,
l0.KSB's,  10QSB's,  Form 8's,  etc. for each of the annual,  quarterly or other
fiscal  periods from the first to latest such filings  since  Licensee  first so
registered as a public company.

         1.6.     Recognition of Licensor Trade Secrets,

                  1.6.1. Licensee agrees that during the term of this Agreement,
         or following its termination and for all times thereafter, it will keep
         secret and  confidential  all Licensor  Trade Secrets which it knows or
         may hereafter come to blow as a result of the relationship  established
         by this Agreement. The Licensor Trade Secrets shall not be disclosed by
         Licensee to third  parties  and shall be kept  secret and  confidential
         except (i) to the  extent  that the same have  entered  into the public
         domain by means other than improper  actions by Licensee or (ii) to the
         extent that the  disclosure  thereof  may be  required  pursuant to the
         order of any court or other governmental body,
<PAGE>

                  1.6.2. It is understood and recognized by Licensee that in the
         event of any violation by Licensee of the  provisions  of  subparagraph
         1.6.2 above,  Licensor's  remedy at law will be inadequate and Licensor
         will  suffer  Irreparable  injury.  Accordingly,  Licensee  consents to
         injunctive and other appropriate  equitable relief upon the institution
         of legal  proceedings  therefor  by  Licensor  in order to protect  the
         Licensor Trade  Secrets.  Such relief shall be in addition to any other
         relief to which Licensor may be entitled at law or in equity.

                  1.6.3.  Licensee  shall cause their  employees  who shall have
         access to Licensor  Trade Secrets  hereof,  to sign  appropriate  Trade
         Secrecy  Agreements in the form of Exhibit B annexed  hereto and made a
         part hereof.

2.       Representations And Warranties Of Licensor

         As an inducement  to, and to obtain the reliance of LICENSEE,  LICENSOR
represents and warrants as follows:

         2.1.  Organization,  Good  Standing,  Power,  Etc.  Licenser  (i.) is a
corporation duly organized, validly existing and in good standing under the laws
of Delaware and (ii) has all requisite corporate power and authority,  licenses,
permits and franchises to own or lease and operate its properties  arid carry on
its business as presently  being  conducted and to execute,  deliver and perform
this Agreement and consummate the transactions contemplated hereby.

         2.2.  Authorization of Agreement,  This Agreement has been or will be
at Closing duly and validly authorized,  executed and delivered by Licensor,

         2.3. Material  Contracts There has not occurred any default by Licensor
or any event which with the lapse of time or the  election of ally person  other
than Licensor will become a default,  except  defaults,  if any,  which will not
result in any material loss to or liability of Licensor.

         2.4.     Permits,  Licenses,  Etc. Licenser has all permits,  licenses,
orders and approvals of federal,  state,  local or foreign  governmental  or
regulatory  bodies  that are  required  in order to permit  it to carry an their
business  as  presently conducted.

         2.5.  Compliance with  Applicable  Laws. The conduct by Licensor of its
business  does not  violate or infringe  upon any  domestic  (federal,  state or
local) or foreign law,  statute,  ordinance or regulation now in effect,  or, to
the knowledge of Licensor proposed to be adopted, the enforcement of which would
materially  and adversely  affect its business or the value of its properties or
assets.

         2.6. Litigation.  There is no material claim, action, suit, proceeding,
arbitration,  investigation  or  inquiry  pending  before  any  federal,  state,
municipal,  foreign or other court or  governmental  or  administrative  body or
agency,  or any private  arbitration  tribunal,  or to the knowledge of Licensor
threatened,  against, relating to or affecting Licensor or any of its properties
or business,  or the  transactions  contemplated by this  Agreement;  nor to the
knowledge of Licensor is there any basis for any such commercial claim,  action,
suit,  proceeding,  arbitration,  Investigation  or  inquiry  which may have any
adverse  effect upon,  the assets,  properties  or business of Licensor,  or the
<PAGE>

transactions  contemplated by this Agreement.  Neither Licensor nor any officer,
director,  partner or employee of Licensor,  has been permanently or temporarily
enjoined  by order,  judgment  or decree of any court or other  tribunal  or any
agency from engaging in or continuing any conduct or practice in connection with
the business  engaged to by  Licensor.  There is not in existence at present any
order, judgment or decree of any court or other tribunal or any agency enjoining
or requiring Licensor to take any material action of any kind or to Licensor and
its  business,  properties  or assets are  subject or bound,  Licensor is not in
default under any order, license,  regulation or demand of any federal, state or
municipal  or other  governmental  agency or with  respect to any  order,  writ,
Injunction or decree of any court which would have a materially  adverse  impact
upon Licensor's operations or affairs.

         2.7. Other  Information.  None of the  information  and documents which
have been furnished or made available by LICENSOR, or any of its representatives
to LICENSEE or any of their  representatives in connection with the transactions
contemplated by this Agreement is materially false or misleading or contains any
material misstatements of fact or omits any material fact necessary to be stated
in order to make the statements therein not misleading.

         2,8.  Covenant  to Refrain  from  trading in Licensee  Securities,  The
Licensor,  its executive officers and directors represent and warrant that since
August 1, 1999 they have not engaged in trading of Licensee securities and until
such time that  Licensee  has  announced  the  Closing  of this  Agreement,  the
Licensor,  its executive  officers and  directors  will not engage in trading of
Licensee securities.

         2.9.     Authority  to Grant a License.  Pursuant to the  Licensor as
the holder of the patents for the  Licensed  Products and the knowledge  and
consent  thereof,  the Licensor has the right and authority to grant the license
set forth in this  Agreement to the Licensor.

         2.10.  Compliance  with  Environmental  Laws Licensor has not caused or
permitted  its  business,   properties,  or  assets  to  be  used  to  generate,
manufacture,  refine,  transport,  treat, store,  handle,  dispose of, transfer,
produce,  or process any Hazardous  Substance  (as such term is defined  herein)
except in compliance with ' all applicable  laws,  rules,  regulations,  orders,
judgments,  and  decrees,  and has not caused or  permitted  the  Release of any
Hazardous  Substance on or off the site of any  property of  Licensor.  The term
'Hazardous  Substance'  shall mean any hazardous waste, as defined by 42 U.S.C.'
6903(5),  any  hazardous  substance,  to  defined by 42 U.S.C.  '  601(14),  any
pollutant  or  contaminant,  as defined by 42 U.S.C.  ' 9601(33),  and all toxic
substances,  hazardous materials,  or other chemical substances regulated by any
other law,  rule, or regulation.  The term 'Release'  shall have the meaning set
forth in 42 U.S.C.' 9601(22).

3.       Marketing And Distribution Licenses

         3.1 Grant of License for AXENOHL,  Subject to Closing of this Agreement
as set forth below,  Licensor  grants to the  Licensee a three year,  license to
market and distribute  AXENOHL for the below described  markets where geographic
exclusivity is detailed.  (EXCLUSIVITY  IS MARKET  SPECIFIC ...See markets below
for  exclusivity)  Provided  there has been no breach of this  Agreement  by the
Licensee  which has not been cured within thirty days of written  notice of such
breach, this geographic license shall automatically renew on terms herein for an
additional  three year terms.  This license does not grant the specific right to
manufacture AXENOHL for the first six months from the date of closing.  However,
if after 6 (six) months alternative means of manufacturing  becomes desirable or
necessary  based on  market  conditions,  IMS will  have the  right or option to
manufacture the AXENOHL  formulations  adhering strictly to NVID specifications.
If NVID cannot  supply  AXENOHL for any reason  within the first six months from
the closing date,  IMS will have the right to  manufacture  AXENOHL prior to the
end of the six-month  period.  IMS will bear the complete cost  associated  with
manufacturing  set-up  and will  offer to provide  NVID the  AXENOHL  product at
manufacturer  cost. In such instance,  NVID will provide the manufacturing  know
how to assist  IMS in  setting  up a  manufacturing  operation  for the  AXENOHL
product for their  respective  markets.  (This does not include the price of the
manufacturing equipment or the price of ETI H20 to set-up the operation.)
<PAGE>

                  3.1.1. Manufactured Price

                           3.1.1:1.  The term  "Manufactured  Price"  as used in
                  this  agreement  shall mean the actual cost to NVID to produce
                  AXENOHL  per  gallon as of the fate  supplied  to It by NVID's
                  supplier thereof.

                  3.1.2.  Point-of-Use  System Market. The Point-of-Use or
         Point-of-Entry  System Market shall be water purification
         and disinfectant  systems for consumer and commercial use. The
         point-of-use  market for water purification shall consist of
         faucet-mount,  countertop and  under-the-counter  models designed
         by or marketed by IMS for residential or commercial water
         disinfections usage. (Exclusive geographical area; Worldwide)

                  3.1.3.  Healthcare  Market. The Healthcare Market shall be all
         water  purification and disinfections  systems for hospitals,  clinics,
         surgical  centers,  doctors' offices or other similar medical or health
         related  facilities,  including military medical and health facilities.
         Exclusive,  license for Australia, North, Central and South America and
         a non-exclusive license for, Costa Rica and other World markets.

                           3.1.3.1. IMS will grant back to NVID a non-exclusive
         right to distribute for this market in Mexico.

                  3.1.4.  AXENOHL  Licensing  Fee.  Commencing  one month  after
         Licensee  sells AXENOHL in the Point of Use System Market or Healthcare
         market,  Licensee  shall pay a Licensing Fee of S70,000  payable at the
         rate of$10,000 per month for (7) seven consecutive months.

                  3.1.5.  AXENOHL,  EPA  Testing  Payments.  Licensee  shall
         be  responsible  for  the  fees  associated  with  EPA
         certification as provided by EPL-Bio-Analytical. Said fees for EPA
         Certification not to exceed $70,000.

                           3.1.5.1. Fees Disbursement

                                    3.1.5.1.1.520,000  will be paid to NVID
                           International,  Inc. upon closing of this  Agreement
                           as partial repayment of invoices already paid to
                           EPL-Bio-Analytical by NVID.

                                    3.1.5.1.2.  The  remaining  balance of up to
                           $50,000  shall be paid to  EPL-Bio-Analytical  at the
                           rate of work actually  performed  monthly  commencing
                           ten (10) days  following  the closing,  and shall not
                           exceed the actual invoice cost of EPL-Bio-Analytical.

                                    3.1.5.1.3.  Royalty.  Subject  to Closing of
                           this Agreement asset forth below,  the Licensee shall
                           pay to  Licensor,  a royalty in the amount of fifteen
                           percent  (15%) of the  actual  manufactured  price of
                           AXENOHL  sold by or  through  the  Licensee  during a
                           calendar  quarter  in the  Point-of-Use  Market.  The
                           Royalty shall be paid on or before the thirtieth (30)
                           day after the close of each calendar  quarter for all
                           AXENOHL for which the  Licensee  has been paid during
                           each calendar quarter adjusted solely for returned or
                           credited product.

                                            3.1.5.1.3.1. Buyer agrees to furnish
                                    Seller  with an  annual  accounting  setting
                                    forth the  number of units sold in the prior
                                    year  concurrently  with the  filing of it's
                                    form 10-SBK.

                  3.1.6. Food Processing  Market.  The Food Processing Market
         shall be water  purification and disinfectant  systems
         for  commercial  human or animal food  preparation  or processing
         operations.  Exclusive,  license for  Australia.  North,
         Central and South America and a non-exclusive license for, Costa Rica
         and other World markets.

                           3.1.6.1.  AXENOHL,  USDA Research  Agreement Payment.
                  Win ten (10 days  following  the  Closing  of this  Agreement,
                  Licensee shall pay the U.S. Department of Agriculture, 529,500
                  for a one year research and testing  agreement to determine if
                  AXENOHL may be approved for use in preparation  and processing
                  of food for human or animal consumption.

                           3.1.6.2.  Exclusive  License  Fees.  IMS will pay to
                  NVID any up-front  licensing  fees  generated by any
                  third  parties for rights to AXENOHL that 1MS may grant in the
                  food  Processing  Market in the  following  manner:
                  Year One: 15% of fee; Year Two 18.5(degree)/a of fee, Year
                  Three 20% of fee, Year Four and thereafter 20"/0.
<PAGE>

                           3.1.6.3.   Royalty.   Subject   to  Closing  of  this
                  Agreement  as set  forth  below,  the  Licensee  shall  pay to
                  Licensor,  a royalty in the amount of fifteen percent (15%) of
                  the  manufactured  price of  AXENOHL  sold by or  through  the
                  Licensee  during a  calendar  quarter  in the Food  Processing
                  Market.  The Royalty  shall be paid on or before the thirtieth
                  (30) day  after  the close of each  calendar  quarter  for all
                  AXENOHL  for which the  Licensee  has been  paid  during  each
                  calendar  quarter  adjusted  solely for  returned  or credited
                  product.

                  3.1.7.  Dental Market, The Dental Market shall be water
                  purification and disinfectant  systems for use by Dentists
                  and Oral Surgeons. (Exclusive geographical area; Worldwide)

                           3.1.7.1.   AXENOHL,   IDS  and  RMS  Dental  Research
                  Agreement  payment.  Upon Closing of this Agreement,  Licensee
                  shall  pay the  actual  cost,  not to  exceed  $17,000  to Dr.
                  Richard   Karpay  for   beginning  the  research  and  testing
                  agreement  to determine  the efficacy of AXENOHL,  IDS and RMS
                  for dental disinfection and bioofilm removal and an additional
                  payment not to exceed S 17,000 upon completion of Dr. Karpay's
                  research.

                           3.1.7.2.   Royalty.   Subject   to  Closing  of  this
                 Agreement  as  set  forth  below,  the  Licensee  shall  pay to
                 Licensor,  a royalty in the amount of fifteen  percent (15%) of
                 the  manufactured  price  of  AXENOHL  sold by or  through  the
                 Licensee  during a calendar  quarter In the Dental Market.  The
                 Royalty shall be paid on or before the thirtieth (30) day after
                 the close of each  calendar  quarter  for all AXENOHL for which
                 the  Licensee  has  been  paid  during  each  calendar  quarter
                 adjusted solely for returned product.

4.       Closing

         4.1.  Closing.  The  Closing of this  Agreement  shall take place on or
before the thirtieth calendar date following execution of this Agreement or such
date as may be agreed upon by the parties,  (herein called the "Closing  Date"),
at the offices of the Licensee.  At the Closing,  each of the respective parties
hereto shall execute,  acknowledge,  and deliver (or shall cause to be executed,
acknowledged,  and delivered) any agreements,  resolutions, or other instruments
required  by this  Agreement  to be so  delivered  at or prior  to the  Closing,
together  with such other items as may be  reasonably  requested  by the parties
hereto and their respective legal counsel in order to effectuate or evidence the
transactions contemplated hereby.

5.        Special Covenants

         5.1. Due  Diligence.  The patties hereto shall have up to and including
the  date  prior to  Closing  within  which  to  complete  their  due  diligence
investigations on the other party and the transaction contemplated hereunder. In
the event either party hereto decides,  in its sole  discretion,  not to proceed
with the Closing based on its due diligence  investigation,  it shall notify the
other in writing of such decision and this  Agreement,  hall  terminate  without
obligation to the other party except as to the confidentiality provisions.

         5.2.  Exchange  of  Information.  Each party shall  cooperate  fully by
exchanging  information requested by the other party in a timely manner. Without
in any manner  reducing or otherwise  mitigating the  representations  contained
herein,  each party and/or its attorneys shall have the opportunity to meet with
the accountants and attorneys of the other party to discuss its respective legal
and  financial  condition  and  this  transaction.  If this  transaction  is not
completed,  all  documents  received by each party and/or its attorney  shall be
returned  to the  other  party and all such  information  so  received  shall be
treated as confidential in accordance with Section x.

6.       Conditions Precedent to Obligations of Parties
<PAGE>

         6.1.     Licensor's  Closing  Conditions.  The obligations of Licensor
         hereunder are subject to fulfillment prior to or at
         the Closing of each of the following conditions:

                  6.1.1. Representations and Warranties, The representations and
         warranties  of Licensee  made  pursuant to Paragraph l above,  shall be
         true and accurate in all material respects as of the Closing Date.

                  6.1.2. Performance, Licensee shall have performed and complied
         with all  agreements  and  conditions  required by this Agreement to be
         performed or complied with by it prior to or at the Closing.

                           6.1.2.1.  Licensee  will  use  reasonable  commercial
                  marketing efforts in Licensees  representations  of all market
                  niches covered in this agreement.

                  6.1.3. No Adverse Changes.  There shall not have been, since
         the date of the latest audited  financial  statements
         of Licensee, any materially adverse change in Licensee's financial
         condition, assets. Liabilities or business.

                  6.1.4.  Opinion of  Licensee's  Counsel.  Licensee  shall have
         delivered  to  Licensor  an  opinion  of  Licensee's  counsel,   Dennis
         Brovarone,  Attorney at Law, dated the Closing Date to the effect that:
         (i) Licensee is a corporation  duly organized,  validly existing and in
         good  standing  under  the  laws of the  State of  California,  has all
         requisite  power to carry on its business as now being conducted and to
         execute,  deliver  and  perform  this  Agreement  and  to  perform  its
         obligations;  (ii)  Licensee  is duly  qualified  to do  business  as a
         foreign  corporation and is good standing in each jurisdiction in which
         the  nature of the  business  conducted  by it or the  property  owned,
         operated or leased by it makes such qualification necessary; (iii) this
         Agreement has been duly authorized by all necessary corporate action on
         the part of Licensee,  has been duly  executed and delivered by IMS and
         constitutes  the  legal,  valid  and  binding  obligation  of  Licensee
         enforceable  in  accordance  with its terms  except  as  enforceability
         thereof may be limited by the  Insolvency  or other laws  affecting the
         rights of creditors and the enforcement of remedies;  (iv) Licensee has
         prepared  and filed with the SEC all  periodic  reports  required of it
         under the 1934 Act; (v) neither the execution, delivery and performance
         by Licensee of this  Agreement,  nor  compliance  by Licensee  with the
         terms and provisions hereof,  will conflict with, or result in a breach
         of the terms, conditions or provisions of, or will constitute a default
         under,  the  Articles  of  Incorporation  or Bylaws of  Licensee or any
         agreement or  instrument  known to such counsel to which  Licensee is a
         party or by which IMS or any of its  properties  or assets  are  bound;
         (vi) there are no  actions,  suits or  proceedings  pending  or, to the
         knowledge of such counsel, threatened against Licensee before any court
         or administrative  agency,  which have, in the opinion of such counsel,
         if  adversely  decided,  will have any material  adverse  effect on the
         business or  financial  condition  of Licensee or which  questions  the
         validity of this Agreement. In rendering his, opinion, counsel shall be
         allowed to rely on written representations of officers and directors of
         the Licensee as to factual  matters  without  independent  verification
         thereof

                  6.1.5.   Current   Status   with   Securities   and   Exchange
         Commission,.  Licensee  shall have prepared arid filed with the SEC all
         periodic  reports required under the 1934 Act pursuant to Section 12(g)
         thereof.

                  6.1.6.  Due Diligence.  Licenser shall have  completed and be
         satisfied  with its due diligence  investigation  of Licensee pursuant
         to Paragraph 5.1.

         6.2.     Licensee's  Closing  Conditions.  The obligations of Licensee
         hereunder are subject to fulfillment prior to or at the Closing of
         each of the following conditions:

                  6.2.1.  Representations and Warrant's, The representations and
         warranties  of Licensor  made  pursuant to paragraph 2 above,  shall be
         true and accurate in all material respects as of the Closing Date.
<PAGE>

                  6.2.2. No Adverse Changes.  There shall not have been, since
         the date of the latest audited  financial  statements of Licensor, any
         materially adverse change in their financial condition, assets,
         liabilities or business.

                  6.2.3.  Opinion  of  Licensee's  Counsel  Licensor  shall have
         delivered to  Licensee,  an opinion of their  counsel,  Mr Curt Crecly,
         Attorney at Law,  respectively,  dated the  Closing  Date to the effect
         that: (i) Licensor is a corporation  duly organized,  validly  existing
         and in good standing  under the laws of the State of Delaware,  has all
         requisite  power to carry on its business as now being conducted and to
         execute,  deliver  and  perform  this  Agreement  and  to  perform  its
         obligations;  (ii) Licensor is duly  qualified to do business and is in
         good standing in each  jurisdiction in which the nature of the business
         conducted by it or the property  owned,  operated or leased by it makes
         such  qualification  necessary;  (iii)  this  Agreement  has been  duly
         authorized  by all necessary  corporate  action on the pan of Licensor,
         has been duly executed and delivered by Licensor arid  constitutes  the
         legal,  valid  and  binding  obligation  of  Licensor,  enforceable  in
         accordance  with its terms  except  as  enforceability  thereof  may be
         limited  by the  insolvency  or other  laws  affecting  the  rights  of
         creditors and the enforcement of remedies;  (iv) neither the execution,
         delivery and performance by Licensor of this Agreement,  nor compliance
         by Licensor with the terms and provisions  hereof,  will conflict with,
         or result in a breach of the terms,  conditions  or  provisions  of, or
         will  constitute  a default  under,  the Articles of  Incorporation  or
         Bylaws of Licensor or any agreement or Instrument known to such counsel
         to  which  Licensor  is a  party  or by  which  Licensor  or any of its
         properties  or assets are  bound;  (v) there are no  actions,  suits or
         proceedings  pending or, to the knowledge of such counsel,.  threatened
         against Licensor before any court or administrative  agency,  which, in
         the  opinion  of such  counsel,  if  adversely  decided,  will have any
         material  adverse  effect on the  business or  financial  condition  of
         Licensor  or  which  questions  the  validity  of  this  Agreement.  In
         rendering  their  opinion,  counsel shall be allowed to rely on written
         representations of officers and directors of the Licensor as to factual
         matters without independent verification thereof.

                  6.2.4.  Due Diligence.  Licensee shall have  completed and be
         satisfied  with its due diligence  investigation  of Licensor pursuant
         to paragraph 5.1.

7.       Patent and Copyright Indemnity.

         7.1.  Licensor  warrants  that the use of the Licensed  Products by the
Licensee  pursuant to the terms hereof shall not constitute an  infringement  of
any existing patent,  copyright or other right. Licensor hereby agrees to defend
or settle any suit,  proceeding or claim brought against the Licensee based on a
claim that the use of the Licensed  Products or any part thereof by the Licensee
constitutes an  Infringement of any existing  patent,  copyright or other right.
Licensor shall pay all damages or costs awarded  against or expenses,  including
attorneys' fees, incurred by the Licensee in such suit, proceeding or claim.

         7.2. In the event the Licensed Products or any part thereof shall be in
Licensees  opinion  likely to or shall become the subject of a claim for patent,
copyright,  or other  Infringement,  Licensor  shall, at its option and expense,
procure for the Licensee the right to continue  using such  affected part of the
Licensed Products or modify such affected part to become non-infringing.  Should
Licensor  elect  to  remove  or  modify  such  infringing  part of the  Licensed
Products,  Licensor  shall  forthwith  replace  such  part  with a  functionally
equivalent  non-infringing  part or take other appropriate action to insure that
the  Licensed  Products  conforms  to  the   Specifications  to  the  Licensee's
satisfaction, without cost to the Licensee.

         7.3.  In the event  that  Licensor  shall  refuse or shall be unable to
supply or shall be prevented  from  supplying the Licensed  Products or any part
thereof to the Licensee,  or in the event that the  Licensee's  continued use of
the Licensed  Products  shall be  prohibited  or enjoined at any time,  Licensor
shall  promptly  replace  all  affected  parts  of the  Licensed  Products  with
functionally equivalent  non-infringing parts of shall take such other action to
insure  that  the  Licensed  products  conforms  to  the  Specifications  to the
Licensee's satisfaction, without cost to the Licensee.
<PAGE>

         7.4.  Licensor  warrants that the Licensee shall suffer ~o interruption
of its  normal  business  activities  or  cycles  as a  result  of  any  claimed
infringement,   any  litigation  referred  to  in  Paragraph  7  hereof  or  any
replacement of items contemplated in paragraph 7 hereof.

8.       Miscellaneous

         8.1. Expense and Further Assurance.  The parties hereto shall each bear
their respective costs and expenses incurred In connection with the transactions
contemplated  by this  Agreement.  Each party  hereto will use its best  efforts
provide  any and all  additional  information,  execute  and deliver any and all
documents or other  written  material and perform any and all acts  necessary to
carry out the intent of this Agreement and to comply with U.S. law.

         8,2.     Survival of Representations,  Warranties and Covenants, All
of the representations,  warranties and covenants made as of the date of this
Agreement and as of Closing, shall survive the closing of this transaction,

         8.3, Successors and Assigns, All representations, warranties, covenants
and  agreements In this  Agreement  shall be binding upon and shall inure to the
benefit of the  parties  hereto  and their  respective  heirs,  representatives,
successors and assigns whether so expressed or not,

         8.4.  Governing Law. This Agreement and the legal  relations  among the
Parties hereto shall be governed by and construed In accordance with the laws of
the State of California and that the State or Federal Courts of California shall
be the jurisdiction in which any legal  proceedings  relative to this Agreement,
shall be brought. The foregoing notwithstanding, the Parties agree that prior to
litigation, they will arbitrate arty disputes relative to this Agreement through
the services of the offices of the American  Arbitration  Association in and for
San Diego, California.

         8.5.  Attorney's  Fees In any action  brought to enforce  the terms and
conditions of this Agreement, the prevailing party shall be entitled in addition
to any other remedies, its reasonable attorneys fees Incurred in the prosecution
or defense of the action.

         8.6.     Section and other  Headings.  The section and other headings
herein  contained are for convenience  only and shall not be construed as part
of this Agreement.

         8.7.     Counterparts.  This Agreement may be executed in any number of
counterparts and each counterpart  shall constitute an original instrument, but
all such separate counterparts shall constitute but one and the same instrument.

         8,8.     Entire  Agreement.  This Agreement  constitutes the entire
agreement between the parties hereto and supersedes all prior agreements,
understandings and arrangements.  oral or written,  between the parties hereto
with respect to the subject matter hereof. This Agreement tray not be amended or
modified, except by a written agreement signed by all parties hereto.

         8.9.     Severability.  Any term or provision  of this  Agreement
which is invalid or  unenforceable  in any  jurisdiction shall, as to such
jurisdiction,  be ineffectual to the extent of such invalidity or
unenforceability  without rendering invalid or unenforceable  the remaining
terms and provisions of this Agreement or affecting the validity or
enforceability of any of the terms or provisions of this Agreement in any other
jurisdiction,

         8.10. Confidentiality.  Each party hereto agrees with the other parties
that, unless and until this Agreement has been  consummated,  or for a period of
one (1) year from the date of this Agreement if the transaction  contemplated by
this Agreement is not consummated it and its representatives will hold in strict
confidence  all data and  information  obtained  with respect to the other patty
<PAGE>

from any  representative,  Officer,  Director or employee,  or from any books or
records or from personal inspection, of such other party, and shall not use such
data or  information or disclose the same to others,  except:  (i) to the extent
such data or information has theretofore been publicly disclosed, is a matter of
public knowledge or Is required by law to be publicly disclosed; and (ii) to the
extent  that  such data or  information  must be used or  disclosed  in order to
consummate  the  transactions  contemplated  by this  Agreement.  The  foregoing
notwithstanding, Licensee shall be authorized to publicly announce the execution
and closing of this Agreement, details thereof and a description of Licensor and
the business conducted thereby.

IN WITNESS WHEREOF,  the corporate  parties hereto have caused this Agreement to
be executed by their respective  Officers,  hereunto duly authorized,  as of the
date first above written.

NVID INTERNATIONAL, INC.

By: David J. Larson, President

By:  Michael J. Redden, Secretary

INNOVATIVE MEDICAL SERVICES

By:  Michael L. Krall, President

By:  Dennis Atchley, Secretary

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]